Document Detail


p53 mutations and expression in ovarian cancers: correlation with overall survival.
MedLine Citation:
PMID:  9891239     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
The p53 gene is altered in approximately 50% of all human malignancies. p53 overexpression, identified by immunohistochemistry, and p53 mutations, identified by single-strand conformational polymorphism (SSCP) and DNA sequencing, have been described in ovarian cancers. p53 overexpression has been correlated with poor outcome for women with ovarian cancer in some studies. With only limited data, the assumption has been made that p53 overexpression corresponds to p53 mutations. The purpose of this investigation was to assess p53 alterations in ovarian cancer to determine if p53 overexpression corresponds with mutations in the p53 gene, and to assess whether either predicts clinical outcome in ovarian carcinoma. Frozen ovarian carcinoma tumor specimens from 105 patients were analyzed by immunohistochemical staining for p53 expression. SSCP was used to screen for mutations and DNA sequencing was used to confirm the specific mutation in exons 2 to 11, encompassing the entire p53 open reading frame. Those ovarian carcinomas identified as wild-type p53 by SSCP were subjected to automated DNA sequence analysis of the entire open reading frame. Relative to DNA sequence analysis, the sensitivity of SSCP was 85% and the specificity was 98%. Immunohistochemical staining demonstrated that 72 of the 105 (69%) cases had positive immunostaining. SSCP and DNA sequencing identified and confirmed mutations in 60 of the 105 carcinomas (57%). Although there was a statistically significant association between p53 immunostaining and p53 mutations (p = 0.0002), false-negative and -positive results were identified. Tumor grade (p = 0.03), stage (p = 0.08), and overall survival (p = 0.15) were moderately associated with positive p53 immunostaining. Patients with p53 mutations and overexpression had shorter overall patient survival (p = 0.02). The findings demonstrated that, individually, p53 mutations and p53 overexpression were each related to shorter patient survival, but the strongest predictor of outcome was a combination of both mutations and overexpression. Comparisons of overall survival for women with mutations in loop 2, loop 3, and the loop-sheet-helix domains together showed a statistically significant difference in survival compared to survival of women whose ovarian cancers had other mutations (p = 0.046).
Authors:
W H Wen; A Reles; I B Runnebaum; J Sullivan-Halley; L Bernstein; L A Jones; J C Felix; R Kreienberg; A el-Naggar; M F Press
Related Documents :
8014109 - P53 gene mutation in hepatocellular carcinoma induced by 2-amino-3-methylimidazo[4,5-f]...
1429209 - High incidence of p53 gene mutation in human ovarian cancer and its association with nu...
19660449 - Caudal regression in adrenocortical dysplasia (acd) mice is caused by telomere dysfunct...
19950209 - Transformation of pleomorphic adenoma to carcinoma ex pleomorphic adenoma of the paroti...
8286219 - The relation between p53 mutation and p53 immunostaining in non-melanoma skin cancer.
12533829 - Diverse p53 alterations in ulcerative colitis-associated low-grade dysplasia: full-leng...
16002759 - Polymorphisms in genes of the endothelin system and cerebral small-vessel disease.
21787189 - Interstitial lung disease in gefitinib-treated japanese patients with non-small-cell lu...
23206699 - Spinocerebellar ataxia type 35 (sca35)-associated transglutaminase 6 mutants sensitize ...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, P.H.S.    
Journal Detail:
Title:  International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists     Volume:  18     ISSN:  0277-1691     ISO Abbreviation:  Int. J. Gynecol. Pathol.     Publication Date:  1999 Jan 
Date Detail:
Created Date:  1999-03-16     Completed Date:  1999-03-16     Revised Date:  2007-11-14    
Medline Journal Info:
Nlm Unique ID:  8214845     Medline TA:  Int J Gynecol Pathol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  29-41     Citation Subset:  IM    
Affiliation:
Department of Pathology, University of Southern California School of Medicine, Los Angeles 90033, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Base Sequence
Female
Genes, p53*
Humans
Immunohistochemistry
Middle Aged
Mutation*
Open Reading Frames
Ovarian Neoplasms / genetics*,  mortality,  pathology
Polymerase Chain Reaction
Polymorphism, Single-Stranded Conformational
Tumor Suppressor Protein p53 / analysis*
Grant Support
ID/Acronym/Agency:
CA48780/CA/NCI NIH HHS; CA50589/CA/NCI NIH HHS; MO1 RR-43/RR/NCRR NIH HHS
Chemical
Reg. No./Substance:
0/Tumor Suppressor Protein p53

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Expression of steroid receptors, Ki-67, and p53 in uterine leiomyosarcomas.
Next Document:  The prognostic significance of p53 expression quantitated by computerized image analysis in epitheli...